Tags

Type your tag names separated by a space and hit enter

ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Histopathology 2016; 69(1):72-83H

Abstract

AIMS

The aim of this study was to elucidate the pathological features of inflammatory myofibroblastic tumour (IMT) with gene rearrangement other than ALK.

METHODS AND RESULTS

We investigated anaplastic lymphoma kinase (ALK), ROS1, ETV6, NTRK3 and RET in 36 cases of IMT by using immunohistochemical (IHC) staining, fluorescence in-situ hybridization, and reverse transcription polymerase chain reaction (RT-PCR). IHC staining showed ALK and ROS1 to be positive in 22 of 36 (61.1%) and two of 36 (5.6%) cases, respectively. In one case with ROS1 positivity, IHC staining showed cytoplasmic and dot-like ROS1 expression, and RT-PCR showed the presence of the TFG-ROS1 fusion transcript. Two cases of pulmonary IMT, in a 7-year-old patient and a 23-year-old patient, had ETV6 rearrangement, and the presence of the ETV6-NTRK3 fusion transcript was confirmed in one case. These tumours were composed of hypocellular myxoid areas and highly cellular areas with rich plasmacytic infiltration; the histological features were different from those of infantile fibrosarcoma. RET rearrangement was not detected.

CONCLUSIONS

These results suggest that a subset of ALK-negative IMTs have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism, and that the detection of these alterations may be of diagnostic value and helpful for determining promising therapeutic strategies.

Authors+Show Affiliations

Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.Department of Pathology and Clinical Laboratories, National Cancer Centre Hospital, Tokyo, Japan.Department of Pathology, National Kyushu Cancer Center, Fukuoka, Japan.Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.Department of Pathology, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan.Department of Pathology, Saga Medical Centre Koseikan, Saga, Japan.Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26647767

Citation

Yamamoto, Hidetaka, et al. "ALK, ROS1 and NTRK3 Gene Rearrangements in Inflammatory Myofibroblastic Tumours." Histopathology, vol. 69, no. 1, 2016, pp. 72-83.
Yamamoto H, Yoshida A, Taguchi K, et al. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology. 2016;69(1):72-83.
Yamamoto, H., Yoshida, A., Taguchi, K., Kohashi, K., Hatanaka, Y., Yamashita, A., ... Oda, Y. (2016). ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology, 69(1), pp. 72-83. doi:10.1111/his.12910.
Yamamoto H, et al. ALK, ROS1 and NTRK3 Gene Rearrangements in Inflammatory Myofibroblastic Tumours. Histopathology. 2016;69(1):72-83. PubMed PMID: 26647767.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. AU - Yamamoto,Hidetaka, AU - Yoshida,Akihiko, AU - Taguchi,Kenichi, AU - Kohashi,Kenichi, AU - Hatanaka,Yui, AU - Yamashita,Atsushi, AU - Mori,Daisuke, AU - Oda,Yoshinao, Y1 - 2016/01/19/ PY - 2015/09/25/received PY - 2015/11/26/accepted PY - 2015/12/10/entrez PY - 2015/12/10/pubmed PY - 2017/7/1/medline KW - ALK KW - ETV6 KW - NTRK3 KW - ROS1 KW - inflammatory myofibroblastic tumour SP - 72 EP - 83 JF - Histopathology JO - Histopathology VL - 69 IS - 1 N2 - AIMS: The aim of this study was to elucidate the pathological features of inflammatory myofibroblastic tumour (IMT) with gene rearrangement other than ALK. METHODS AND RESULTS: We investigated anaplastic lymphoma kinase (ALK), ROS1, ETV6, NTRK3 and RET in 36 cases of IMT by using immunohistochemical (IHC) staining, fluorescence in-situ hybridization, and reverse transcription polymerase chain reaction (RT-PCR). IHC staining showed ALK and ROS1 to be positive in 22 of 36 (61.1%) and two of 36 (5.6%) cases, respectively. In one case with ROS1 positivity, IHC staining showed cytoplasmic and dot-like ROS1 expression, and RT-PCR showed the presence of the TFG-ROS1 fusion transcript. Two cases of pulmonary IMT, in a 7-year-old patient and a 23-year-old patient, had ETV6 rearrangement, and the presence of the ETV6-NTRK3 fusion transcript was confirmed in one case. These tumours were composed of hypocellular myxoid areas and highly cellular areas with rich plasmacytic infiltration; the histological features were different from those of infantile fibrosarcoma. RET rearrangement was not detected. CONCLUSIONS: These results suggest that a subset of ALK-negative IMTs have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism, and that the detection of these alterations may be of diagnostic value and helpful for determining promising therapeutic strategies. SN - 1365-2559 UR - https://www.unboundmedicine.com/medline/citation/26647767/ALK_ROS1_and_NTRK3_gene_rearrangements_in_inflammatory_myofibroblastic_tumours_ L2 - https://doi.org/10.1111/his.12910 DB - PRIME DP - Unbound Medicine ER -